[go: up one dir, main page]

WO2002011695A3 - Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum - Google Patents

Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum Download PDF

Info

Publication number
WO2002011695A3
WO2002011695A3 PCT/US2001/024632 US0124632W WO0211695A3 WO 2002011695 A3 WO2002011695 A3 WO 2002011695A3 US 0124632 W US0124632 W US 0124632W WO 0211695 A3 WO0211695 A3 WO 0211695A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhaleable
spray dried
helix bundle
protein powders
bundle protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024632
Other languages
English (en)
Other versions
WO2002011695A2 (fr
Inventor
Cynthia Stevenson
Jayne E Hastedt
S Russ Lehrman
Hi-Shi Chiang
David B Bennett
David Lesikar
Bing Yang
David Gong
Kirsten Cabot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Inhale Therapeutics Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutics Systems Inc filed Critical Inhale Therapeutics Systems Inc
Priority to EP01959572A priority Critical patent/EP1309312A2/fr
Priority to JP2002517033A priority patent/JP2004515467A/ja
Priority to MXPA03001092A priority patent/MXPA03001092A/es
Priority to KR10-2003-7001831A priority patent/KR20030038690A/ko
Priority to AU2001281113A priority patent/AU2001281113B2/en
Priority to CA002418960A priority patent/CA2418960A1/fr
Priority to AU8111301A priority patent/AU8111301A/xx
Publication of WO2002011695A2 publication Critical patent/WO2002011695A2/fr
Publication of WO2002011695A3 publication Critical patent/WO2002011695A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J29/00—Details of, or accessories for, typewriters or selective printing mechanisms not otherwise provided for
    • B41J29/12—Guards, shields or dust excluders
    • B41J29/13—Cases or covers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00—Inks
    • C09D11/30—Inkjet printing inks

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/US2001/024632 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum Ceased WO2002011695A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP01959572A EP1309312A2 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
JP2002517033A JP2004515467A (ja) 2000-08-07 2001-08-06 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
MXPA03001092A MXPA03001092A (es) 2000-08-07 2001-08-06 Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
KR10-2003-7001831A KR20030038690A (ko) 2000-08-07 2001-08-06 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말
AU2001281113A AU2001281113B2 (en) 2000-08-07 2001-08-06 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
CA002418960A CA2418960A1 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
AU8111301A AU8111301A (en) 2000-08-07 2001-08-06 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22314400P 2000-08-07 2000-08-07
US60/223,144 2000-08-07
US22863400P 2000-08-29 2000-08-29
US60/228,634 2000-08-29
US24047800P 2000-10-13 2000-10-13
US60/240,478 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002011695A2 WO2002011695A2 (fr) 2002-02-14
WO2002011695A3 true WO2002011695A3 (fr) 2002-04-25

Family

ID=27397184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024632 Ceased WO2002011695A2 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum

Country Status (10)

Country Link
US (3) US6569406B2 (fr)
EP (1) EP1309312A2 (fr)
JP (1) JP2004515467A (fr)
KR (1) KR20030038690A (fr)
CN (1) CN1446077A (fr)
AU (2) AU8111301A (fr)
CA (1) CA2418960A1 (fr)
MX (1) MXPA03001092A (fr)
TW (1) TWI283182B (fr)
WO (1) WO2002011695A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3717925B2 (ja) * 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
CA2190502A1 (fr) * 1994-05-18 1995-11-23 Robert M. Platz Procedes et compositions pour produire des interferons sous forme de poudre seche
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
DK1458360T3 (da) 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
EP1485073A2 (fr) * 2002-03-20 2004-12-15 Advanced Inhalation Research, Inc. Technique d'administration d'hormone de croissance par voie pulmonaire
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
JP2006199589A (ja) * 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
US7024866B2 (en) * 2003-12-11 2006-04-11 Helix Technology Corporation Axial loaded seal system with a static L-seal
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
JP2007522246A (ja) * 2004-02-12 2007-08-09 ネクター セラピューティクス インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
CN100574801C (zh) * 2004-04-07 2009-12-30 阿雷斯贸易股份有限公司 液体生长激素制剂
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
JP4147235B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
EP1830810A4 (fr) * 2004-12-30 2011-02-02 Dobeel Co Ltd Préparation séchée par atomisation contenant des protéines de la famille de la collectine ou des variantes desdites protéines, et procédé d'élaboration de ladite préparation
ES2640282T3 (es) * 2005-09-14 2017-11-02 Mannkind Corporation Método de formulación de fármacos basado en el aumento de la afinidad de superficies de micropartículas cristalinas para agentes activos
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20080035141A1 (en) * 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
CA2655660A1 (fr) * 2006-07-20 2008-01-24 Sicor Inc. Procede de preparation d'un ingredient pharmaceutique actif sterile solide
US7746769B2 (en) * 2007-03-26 2010-06-29 Alcatel Lucent Management of redundant and multi-segment pseudo-wire
WO2008121301A1 (fr) 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-il-12 humains cristallins
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation
US20090145433A1 (en) * 2007-12-08 2009-06-11 Michael James Apparatus for dispensing a powdered composition into the aerodigestive tract
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
WO2009152477A2 (fr) 2008-06-13 2009-12-17 Mannkind Corporation Inhalateur de poudre sèche et système d’administration de médicament
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2300083T3 (da) 2008-06-20 2013-07-22 Mannkind Corp Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CA2748490C (fr) 2008-12-29 2016-10-04 Mannkind Corporation Analogues substitues de dicetopiperazine pour une utilisation en tant qu'agents d'administration de medicaments
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et methode de simulation d'efforts d'inhalation
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP2014504260A (ja) * 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
JP2014522827A (ja) 2011-06-28 2014-09-08 ロイコケア・アクチェンゲゼルシャフト （ポリ）ペプチドのアンフォールディングを防止し、および／または（ポリ）ペプチドの（リ）フォールディングを誘導するための方法
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
PL3384903T3 (pl) 2011-11-18 2020-10-19 Regeneron Pharmaceuticals, Inc. Mikrocząsteczka zawierająca białko terapeutyczne powleczone biodegradowalnym polimerem do zastosowania medycznego
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
RU2650035C2 (ru) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN108578372B (zh) 2013-03-15 2021-07-06 曼金德公司 微晶二酮哌嗪组合物以及方法
HK1218855A1 (zh) 2013-04-30 2017-03-17 Otitopic Inc. 干粉製劑及使用方法
CA2918369C (fr) 2013-07-18 2021-06-29 Mannkind Corporation Compositions pharmaceutiques en poudre seche stables a la chaleur et procedes
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
PL3107548T3 (pl) 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji
US10857315B2 (en) * 2014-02-21 2020-12-08 David Brown Inhalation device and method for inhaling powders
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
GB201419900D0 (en) * 2014-11-07 2014-12-24 Dupont Nutrition Biosci Aps Method
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
SG11201809594WA (en) * 2016-06-30 2018-11-29 Philip Morris Products Sa Nicotine particles and compositions
EP3592352A1 (fr) * 2017-03-07 2020-01-15 Philip Morris Products S.a.s. Formulations de nicotine à inhaler et procédés de production et d'utilisation de celles-ci
JP7637618B2 (ja) * 2018-11-21 2025-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
CN111598399B (zh) * 2020-04-17 2023-04-28 西安理工大学 基于分布式计算平台的超大规模输电网络扩展规划方法
KR20230125383A (ko) 2022-02-21 2023-08-29 주식회사 홀블렌딩 식물성 단백질 파우더 및 그 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001032144A1 (fr) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Compositions de poudre seche a dispersivite amelioree

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0257956B2 (fr) 1986-08-19 2000-11-22 Genentech, Inc. Usage de facteurs de croissance et de cytocines polypeptides pour fabriquer un dispositif et une dispersion
EP0303746B2 (fr) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisation des hormones de croissance
CA1331133C (fr) 1988-03-01 1994-08-02 Michael Jon Pikal Formulations pharmaceutiques d'hormone de croissance humaine
US5763394A (en) 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
DK168790D0 (fr) 1990-07-13 1990-07-13 Novo Nordisk As
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
SE467525B (sv) 1990-10-09 1992-08-03 Nemo Ivarson Ab Foerfarande foer att oeverdraga fasta partiklar i pulverform med ett i rumstemperatur hoegviskoest eller fast material
WO1992014449A1 (fr) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Systeme d'administration microparticulaire a liberation regulee pour des proteines
WO1992017200A2 (fr) 1991-03-28 1992-10-15 Genentech, Inc. Formulations stables a base d'ion metal et d'hormone de croissance
ATE119805T1 (de) 1991-07-11 1995-04-15 Glatt Gmbh Verfahren und einrichtung zum beschichten von teilchen.
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
RO111990B1 (ro) 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
AU3582893A (en) 1992-01-13 1993-08-03 Pitman-Moore, Inc. Delayed release device for transition metal/protein complexes
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO1994012158A1 (fr) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Microspheres contenant une hormone de croissance a liberation regulee
NZ262634A (en) 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
JP3349540B2 (ja) 1993-03-10 2002-11-25 フロイント産業株式会社 造粒方法および装置
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
WO1995001164A1 (fr) 1993-06-30 1995-01-12 Genentech, Inc. Procede de preparation de liposomes
JPH07232049A (ja) 1994-02-25 1995-09-05 Freunt Ind Co Ltd 遠心転動造粒コーティング装置および粉粒体の遠心転動造粒コーティング方法ならびにその方法を用いた粉粒体の造粒方法とコーティング方法
JP2886446B2 (ja) 1994-03-03 1999-04-26 関西ペイント株式会社 塗膜保護用シート
DK0804223T3 (da) 1994-06-17 2000-01-24 Applied Research Systems Farmaceutiske præparater indeholdende hGH
US5641510A (en) 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
IL115592A (en) 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
WO1996021460A1 (fr) 1995-01-13 1996-07-18 Novo Nordisk A/S Formulation pharmaceutique stabilisee comprenant une hormone de croissance et lys-x
US5705482A (en) 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US6004583A (en) 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5552385A (en) 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
ZA965367B (en) 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
DE69635026T2 (de) 1995-09-21 2006-05-24 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JP3839531B2 (ja) 1996-11-05 2006-11-01 フロイント産業株式会社 遠心転動造粒コーティング装置およびこれを用いた粉粒体の造粒方法ならびにコーティング方法
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
ES2289823T3 (es) 1998-08-25 2008-02-01 Advanced Inhalation Research, Inc. Formulaciones proteicas estables secadas por atomizacion.
US6197369B1 (en) 1999-09-30 2001-03-06 New Jersey Institute Of Technology Method of particle coating
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
WO2001032144A1 (fr) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Compositions de poudre seche a dispersivite amelioree

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7384649B2 (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery

Also Published As

Publication number Publication date
US6569406B2 (en) 2003-05-27
US20030190291A1 (en) 2003-10-09
KR20030038690A (ko) 2003-05-16
US20050186143A1 (en) 2005-08-25
MXPA03001092A (es) 2003-09-25
CN1446077A (zh) 2003-10-01
TWI283182B (en) 2007-07-01
CA2418960A1 (fr) 2002-02-14
US6838075B2 (en) 2005-01-04
JP2004515467A (ja) 2004-05-27
WO2002011695A2 (fr) 2002-02-14
EP1309312A2 (fr) 2003-05-14
AU8111301A (en) 2002-02-18
US20020065399A1 (en) 2002-05-30
AU2001281113B2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
AU8111301A (en) Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1307256A4 (fr) Inhalateur de poudre seche
SI1294421T1 (sl) Suhoprašni inhalator
ZA200105453B (en) Potentiation of Anti-CD38-immunotoxin cytotoxicity.
AU1331802A (en) Cd38 modulated chemotaxis
AU2188402A (en) Delta 1-pyrrolines used as pesticides
AU2002225664A1 (en) A sprayer container comprising a fabric treatment composition
GB2373455B (en) Dynamic collapsible revolving toy
GB2352736B (en) Sparkle linen spray
TW543764U (en) Rotary dryer
AU146091S (en) Hair dryer
GB0001115D0 (en) Hand dryer
HRPK20000355B1 (en) Electro-compressor knapsack sprayer
AU1752601A (en) Dry powder inhaler
IL153556A0 (en) Novispirins: antimicrobial peptides
EP1444916A4 (fr) Sechoir
HUP0302964A3 (en) Delta 1-pyrrolines, intermediates, preparation thereof and their use as pesticides
AU142299S (en) Hair dryer
GB2365335B (en) Hairdryer
GB0113028D0 (en) Powder applicator
GB0000482D0 (en) Enteric coated pharmaceutical formulation
GB0017444D0 (en) Dry sprayer
GB0405457D0 (en) Sparkle linen spray
TW416265U (en) Improved sprayer
AU145494S (en) Lotion sprayer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001281113

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018137962

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001092

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2418960

Country of ref document: CA

Ref document number: 2002517033

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037001831

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001959572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001959572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037001831

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642